GlassScriptPhysician profile
Jose A Sanchez
NPI 1982600623
$15,979.61
in general payments reported to CMS, 2019-2025
62 companies · $2,610 in 2025
The $2,610 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,778 · 2020: $1,992 · 2021: $2,254 · 2022: $1,746 · 2023: $1,871 · 2024: $2,728 · 2025: $2,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,209.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,659.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,038.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,827.89 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $1,275.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,170.10 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $911.01 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $696.39 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $696.14 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Pfizer INC. | $489.10 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $400.73 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $369.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $366.17 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $362.44 | 2020-2024 | Nexletol |
| Intuitive Surgical, INC. | $240.95 | 2019-2025 | |
| Eisai INC. | $233.99 | 2020-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.